| Assessment Status |
NCPE Assessment Process Complete |
| HTA ID |
- |
| Drug |
Alemtuzumab |
| Brand |
Lemtrada® |
| Indication |
For adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features |
| Rapid review commissioned |
08/11/2013 |
| Rapid review completed |
02/12/2013 |
| Rapid review outcome |
Full HTA Assessment Recommended |
| Full submission received from Applicant |
28/01/2014 |
| NCPE assessment completed |
25/06/2014 |
| NCPE assessment outcome |
The NCPE recommends reimbursement of alemtuzumab (Lemtrada®). |
